References
1. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - Renewing consensus in portal hypertension.Journal of hepatology 2022; 76 (4): 959-74.
2. Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension.The lancet Gastroenterology & hepatology 2018; 3 (10): 708-19.
3. Villanueva C, Albillos A, Genesca J, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393 (10181): 1597-608.
4. Abraldes JG, Bureau C, Stefanescu H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The ”Anticipate” study. Hepatology 2016;64 (6): 2173-84.
5. Banini BA, Patel S, Yu JW, et al. Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4. Journal of clinical gastroenterology 2022.
6. Kim TY, Jeong WK, Sohn JH, Kim J, Kim MY, Kim Y. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients.Liver international : official journal of the International Association for the Study of the Liver 2015; 35 (11): 2416-24.
7. Kitson MT, Roberts SK, Colman JC, Paul E, Button P, Kemp W. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scandinavian journal of gastroenterology 2015; 50 (4): 462-9.
8. Jiang FR, Yan HD. Risk factors of clinically significant portal hypertension in patients with compensated liver cirrhosis based on hepatic venous pressure gradient. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2021;29 (10): 995-1000.
9. Jansen C, Bogs C, Verlinden W, et al. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. Liver international : official journal of the International Association for the Study of the Liver2017; 37 (3): 396-405.
10. Dajti E, Ravaioli F, Marasco G, et al. A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. The American journal of gastroenterology 2022; 117 (11): 1825-33.
11. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372 : n71.
12. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine 2011; 155 (8): 529-36.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-60.
14. Jiang W, Wang J, Shen X, et al. Establishment and Validation of a Risk Prediction Model for Early Diabetic Kidney Disease Based on a Systematic Review and Meta-Analysis of 20 Cohorts. Diabetes Care2020; 43 (4): 925-33.
15. Liu C, Li J, Wong YJ, et al. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.Hepatology international 2022; 16 (5): 1105-15.
16. Liu C, Cao Z, Yan H, et al. A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study. The American journal of gastroenterology 2022; 117 (10): 1605-13.
17. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nature reviews Gastroenterology & hepatology 2009; 6 (10): 573-82.
18. Wong YJ, Zhaojin C, Tosetti G, et al. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients. Clinical and molecular hepatology 2022.
19. European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. Journal of hepatology 2021; 75 (3): 659-89.
20. Qi X, An W, Liu F, et al. Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. Radiology 2019;290 (2): 370-7.
21. Liu Y, Ning Z, Ormeci N, et al. Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020; 18 (13): 2998-3007 e5.
22. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133 (2): 481-8.
23. Yu Q, Xu C, Li Q, et al. Spleen volume-based non-invasive tool for predicting hepatic decompensation in people with compensated cirrhosis (CHESS1701). JHEP Rep 2022; 4 (11): 100575.
24. Gidener T, Ahmed OT, Larson JJ, et al. Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2021; 19 (9): 1915-24 e6.
25. Liu Y, Liu C, Li J, Kim TH, Enomoto H, Qi X. Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102). Journal of hepatology2022; 76 (1): 248-50.
26. Wong YJ, Li J, Liu C, et al. CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study. Journal of gastroenterology and hepatology 2022; 37 (6): 1043-51.
27. Garcia-Tsao G, Abraldes JG. Nonselective Beta-Blockers in Compensated Cirrhosis: Preventing Variceal Hemorrhage or Preventing Decompensation? Gastroenterology 2021; 161 (3): 770-3.
28. Villanueva C, Torres F, Sarin SK, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. Journal of hepatology 2022;77 (4): 1014-25.
29. Serper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology 2022.
30. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. The New England journal of medicine 2005; 353 (21): 2254-61.